NEW YORK, October 19, 2016 /PRNewswire/ --
This morning Stock-Callers.com has initiated research reports on these four healthcare stocks: Endologix Inc. (NASDAQ: ELGX), TransEnterix Inc. (NYSE MKT: TRXC), Becton, Dickinson and Company (NYSE: BDX), and OraSure Technologies Inc. (NASDAQ: OSUR) following a bullish session yesterday where gains were broad based as all sectors ended in black. Following suit on Tuesday, October 18, 2016, the NASDAQ Composite ended the trading session at 5,243.84, up 0.85%; the Dow Jones Industrial Average edged 0.42% higher, to finish at 18,161.94; and the S&P 500 closed at 2,139.60, up 0.62%. Download the free research reports on these stocks today:
On Tuesday, shares in Irvine, California headquartered Endologix Inc. ended the session 2.72% higher at $12.48 with a total volume of 482,166 shares traded. Shares of Endologix, which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the US and internationally, are trading 0.94% above its 50-day moving average and 13.63% above its 200-day moving average. Moreover, shares of the Company have a Relative Strength Index (RSI) of 49.58. See our free and comprehensive research report on ELGX at:
Morrisville, North Carolina headquartered TransEnterix Inc.'s stock finished Tuesday's session 1.08% higher at $1.88 with a total volume of 557,173 shares traded. Over the last one month and the previous three months, TransEnterix's shares have surged 27.89% and 46.88%, respectively. The Company's shares are trading above its 50-day moving average by 20.76%. Shares of TransEnterix, which focuses on the development and commercialization of surgical robotic systems, have an RSI of 56.77. TRXC free research report PDF is just a click away at:
Franklin Lakes, New Jersey headquartered Becton, Dickinson and Co.'s stock edged 0.73% higher, to close the day at $172.79. The stock recorded a trading volume of 649,111 shares. Shares of Becton, Dickinson, which develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide, have gained 25.50% in the past one year. The Company's shares are trading 6.95% above its 200-day moving average. Additionally, the stock traded at a PE ratio of 32.93 and has an RSI of 43.75.
On September 23rd, 2016, research firm Citigroup downgraded the Company's stock rating from 'Neutral' to 'Sell'. Sign up for your complimentary report on BDX at:
On Tuesday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 355,229 shares. The stock ended the day 1.43% higher at $7.81. Shares of the Company, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, are trading at a PE ratio of 35.66. OraSure Technologies' stock has gained 20.90% in the previous three months and 59.06% in the past one year. The Company is trading above its 200-day moving average by 11.20%. Furthermore, shares of OraSure Technologies have an RSI of 47.32. Register for free on Stock-Callers.com and download the latest research report on OSUR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA